科兴生物制药股份有限公司

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

浙江博锐生物制药股份有限公司

<p>Chongqing Claruvis Pharmaceutical Co., Ltd. has received marketing approval from China's National Medical Products Administration for Retoxin®, the world's first recombinant botulinum toxin type A. This innovative drug offers a safer and more effective treatment for moderate-to-severe glabellar lines and is also being developed for adult upper limb spasticity. The approval marks a significant technological advancement in botulinum toxin therapy, transitioning from traditional extraction methods to precision-engineered recombinant production. Claruvis aims to expand its pipeline of recombinant products for various neurological and aesthetic applications.</p>

prnewswire

08:38 ETWorld's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

516930

159892

516820

159992

516610

<p>UBS has lowered the target price for SINO BIOPHARM to 11 yuan, maintaining a "Buy" rating. The report pointed out that last year the company's revenue was 31.8 billion yuan, a year-on-year increase of 10.3%, which was below expectations; net profit was 2.3 billion yuan, a year-on-year increase of 22%, also below expectations. The gross profit margin rose to 82.1%. Management expects double-digit growth in both revenue and profit this year. Although the earnings per share forecast for this year has been raised by 9.4%, the earnings per share forecasts for 2027 and 2028 have been lowered due to lower expectations for generic drug revenue</p>

AASTOCKS

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

Guotai CSI Bio-medicine ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Lishengpharma

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

SBP GROUP

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy"

科兴生物制药股份有限公司(N25317.HK)

08:38 ETWorld's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy"